Nvidia stock has been at the center of the artificial intelligence (AI) revolution for three years, but another chip stock ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research ...

Nancy Pelosi, a frequent and often controversial stock trader, has made just one market move since Donald Trump began his ...

Databricks is one of the most valuable start-ups in the world and could seek a public offering driven by strong tailwinds in the artificial intelligence (AI) industry.

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

With a trading volume of 7,459,075, the price of TEM is down by -4.37%, reaching $59.29. Current RSI values indicate that the stock is is currently neutral between overbought and oversold. Next ...

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

Tempus AI, Inc. TEM recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in ...

Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

Tempus AI (TEM) recently secured FDA clearance for its Tempus ECG-Low EF software and expanded its collaboration with Personalis for colorectal cancer detection, measures that collectively ...

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school ...